Mangalam Drugs & OrganicsNSE:MANGALAM +1.07%43 Days Payable is 146.88 as of Mar. 2026, which is 83% above its 10-year median of 80.28. GuruFocus rates NSE:MANGALAM with a GF Score™ of 43/100 and a GF Value™ of ₹63.13 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Mangalam Drugs & Organics ranks better than 81.34% on this metric.
The historical rank and industry rank for Mangalam Drugs & Organics's Days Payable or its related term are showing as below:
NSE:MANGALAM'
s Days Payable Range Over the Past 10 Years
Min: 37.35 Med: 80.28 Max: 194.35
Current: 180.81
During the past 13 years, Mangalam Drugs & Organics's highest Days Payable was 194.35. The lowest was 37.35. And the median was 80.28.
NSE:MANGALAM's Days Payable is ranked better than 81.34% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:MANGALAM: 180.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MANGALAM vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangalam Drugs & Organics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Days Payable distribution charts can be found below:
* The bar in red indicates where Mangalam Drugs & Organics's Days Payable falls into.
Mangalam Drugs & Organics Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mangalam Drugs & Organics's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangalam Drugs & Organics (NSE:MANGALAM) has a Days Payable of 146.88 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mangalam Drugs & Organics and its competitors. This is 83% above median its historical median of 80.28. Over the past decade, Mangalam Drugs & Organics' Days Payable has ranged from 37.35 to 194.35. According to the industry distribution chart, Mangalam Drugs & Organics ranks #172 out of 922 companies in the Drug Manufacturers industry, placing it in the top 18.7%.
Is Mangalam Drugs & Organics' Days Payable too high?
Mangalam Drugs & Organics' current Days Payable of 146.88 is 83% above median its 10-year median of 80.28. Over the past 10 years, this metric has ranged from a low of 37.35 to a high of 194.35. The Drug Manufacturers industry median Days Payable is 90.84. Mangalam Drugs & Organics' value of 146.88 is 61.7% above this industry median. Based on the distribution chart, Mangalam Drugs & Organics ranks #172 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mangalam Drugs & Organics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mangalam Drugs & Organics ranks #172 out of 922 companies for Days Payable. This places Mangalam Drugs & Organics in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Mangalam Drugs & Organics' value of 146.88 is 61.7% above this benchmark. Historically, Mangalam Drugs & Organics' own Days Payable has ranged from 37.35 to 194.35 over the past decade. While the company's 10-year median is 80.28 vs. the industry median of 90.84, Mangalam Drugs & Organics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mangalam Drugs & Organics's current Days Payable of 146.88 is 61.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mangalam Drugs & Organics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangalam Drugs & Organics's current Days Payable is 146.88, which is 83% above median its own 10-year median of 80.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹63.13, compared to a current price of ₹28.44 — trading 55% below its estimated fair value. The current Days Payable is 146.88, which is 83% above median its 10-year median of 80.28 and 61.7% above the Drug Manufacturers industry median of 90.84. Mangalam Drugs & Organics' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Days Payable is 146.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?
Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued.
The current stock price of ₹28.44 is trading 55% below its estimated GF Value™ of ₹63.13.
GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.
Key valuation signals for NSE:MANGALAM:
Days Payable: 146.88 (83% above median its 10-year median of 80.28)
GF Value™: ₹63.13 vs. price of ₹28.44 (55% below fair value)
Industry Position: 61.7% above the Drug Manufacturers median (#172 of 922)
No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score
Get the complete analysis for NSE:MANGALAM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MANGALAM has been successfully added to your 
